Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

Clovis Oncology Inc. stock CLVS, +19.83% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75...

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

Clovis Oncology Inc. shares CLVS, -71.62% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company ...